Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Sci Rep ; 13(1): 22178, 2023 12 13.
Article in English | MEDLINE | ID: mdl-38092810

ABSTRACT

Percutaneous drainage is a first-line therapy for abscesses and other fluid collections. However, experimental data on the viscosity of body fluids are scarce. This study analyses the apparent viscosity of serous, purulent and biliary fluids to provide reference data for the evaluation of drainage catheters. Serous, purulent and biliary fluid samples were collected during routine drainage procedures. In a first setup, the apparent kinematic viscosity of 50 fluid samples was measured using an Ubbelohde viscometer. In a second setup, the apparent dynamic viscosity of 20 fluid samples obtained during CT-guided percutaneous drainage was measured using an in-house designed capillary extrusion experiment. The median apparent kinematic viscosity was 0.96 mm2/s (IQR 0.90-1.15 mm2/s) for serous samples, 0.98 mm2/s (IQR 0.97-0.99 mm2/s) for purulent samples and 2.77 mm2/s (IQR 1.75-3.70 mm2/s) for biliary samples. The median apparent dynamic viscosity was 1.63 mPa*s (IQR 1.27-2.09 mPa*s) for serous samples, 2.45 mPa*s (IQR 1.69-3.22 mPa*s) for purulent samples and 3.50 mPa*s (IQR 2.81-3.90 mPa*s) for biliary samples (all differences p < 0.01). Relative to water, dynamic viscosities were increased by a factor of 1.36 for serous fluids, 2.26 for purulent fluids, and 4.03 for biliary fluids. Serous fluids have apparent viscosities similar to water, but biliary and purulent fluids are more viscous. These data can be used as a reference when selecting the drainage catheter size, with 8F catheters being appropriate for most percutaneous drainage cases.


Subject(s)
Abscess , Drainage , Humans , Viscosity , Drainage/methods , Abscess/therapy , Catheters , Water
2.
Cardiovasc Intervent Radiol ; 44(10): 1625-1632, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34254176

ABSTRACT

PURPOSE: The purpose of this study was to evaluate the predictive value of a 'Modified Karnofsky Scoring System' on outcomes and provide real-world data regarding the UK practice of biliary interventions. MATERIALS AND METHODS: A prospective multi-centred cohort study was performed. The pre-procedure modified Karnofsky score, the incidence of sepsis, complications, biochemical improvement and mortality were recorded out to 30 days post procedure. RESULTS: A total of 292 patients (248 with malignant lesions) were suitable for inclusion in the study. The overall 7 and 30 day mortality was 3.1% and 16.1%, respectively. The 30 day sepsis rate was 10.3%. In the modified Karnofsky 'high risk' group the 7 day mortality was 9.7% versus 0% for the 'low risk' group (p = 0.002), whereas the 30 day mortality was 28.8% versus 13.3% (p = 0.003). The incidence of sepsis at 30 days was 19% in the high risk group versus 3.3% at the low risk group (p = 0.001) CONCLUSION: Percutaneous biliary interventions in the UK are safe and effective. Scoring systems such as the Karnofsky or the modified Karnofsky score hold promise in allowing us to identify high risk groups that will need more careful consideration and enhanced patient informed consent but further research with larger studies is warranted in order to identify their true impact on patient selection and outcomes post biliary interventions.


Subject(s)
Biliary Tract Surgical Procedures , Cholestasis , Cholestasis/surgery , Cohort Studies , Drainage , Humans , Prospective Studies , Treatment Outcome
3.
Cureus ; 13(3): e14121, 2021 Mar 26.
Article in English | MEDLINE | ID: mdl-33927929

ABSTRACT

Malignant obstruction of the cervical esophagus presents some anatomical and technical challenges when considering radiologic or endoscopic intervention. This case report describes the failure of antegrade access to place a gastrostomy tube and stent due to complete luminal occlusion from an esophageal tumor. The ultrasound-guided percutaneous gastric puncture was performed to achieve retrograde pneumodistension to allow radiologic gastrostomy insertion. Subsequently, the cervical esophagus was retrogradely cannulated via insertion of a guidewire from the gastrostomy site. A distal release esophageal stent was then inserted over the wire and deployed from the mouth in an antegrade manner. However, due to the unpredictable proximal shortening of distal release stents, this stent was eventually shortened and displaced so that it no longer covered the top of the tumor stricture, and further antegrade access failed. Once more, a retrograde access approach was adopted via the gastrostomy stoma, a guidewire and catheter were passed retrogradely through the original stent and out through the mouth. A distal release stent system was then inserted in a retrograde manner via the gastrostomy stoma, effectively making it a proximal release stent which enabled more precise positioning of the stent above the tumor. Palliation was achieved until death, and beyond expected mean survival.

4.
J Palliat Care ; 35(2): 93-102, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31448682

ABSTRACT

Malignant bowel obstruction (MBO) is a common manifestation in patients with advanced intra-abdominal malignancy. It is especially common with bowel or gynecological cancers and produces distressing symptoms, including nausea, vomiting, and pain. Medical management options are less effective than decompressive strategies for symptom control. Surgery is the gold-standard treatment but is unsuitable for most patients with high complication rates. Consensus guidelines recommend nonsurgical management with a venting gastrostomy in those unsuitable for surgery or for whom medical management is ineffective. The aim of this systematic review is to establish the safety and efficacy of percutaneous venting gastrostomy in relieving symptoms of MBO. Twenty-five studies were included in this review comprising 1194 patients. Gastrostomy insertion was successful at first attempt in 91% of cases and reduction in symptoms of nausea and vomiting was reported in 92% of cases. Mean survival following the procedure ranged from 35 to 147 days. Major complications were rare, with most complications classed as minor wound infections or leakage of fluid around the tube. Studies suggest that the presence of ascites is not an absolute contraindication to the insertion of percutaneous venting gastrostomy in patients with MBO; however, these studies lack longitudinal outcomes and complication rates related to this. However, it is reasonable to suggest that ascitic drainage is performed to reduce potential complications. There is a relative lack of good quality robust data on the utilization of percutaneous venting gastrostomy in MBO, but overall, the combination of being a safe and efficacious procedure alongside the known complication profile suggests that it should be considered a suitable management option.


Subject(s)
Gastrostomy/methods , Intestinal Obstruction/etiology , Intestinal Obstruction/therapy , Neoplasms/complications , Humans
5.
Br J Radiol ; 91(1091): 20170935, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29888981

ABSTRACT

Oesophageal stents are widely used for palliating dysphagia from malignant obstruction. They are also used with increasing frequency in the treatment of oesophageal perforation, as well as benign strictures from a variety of causes. Improved oncological treatments have led to prolonged survival of patients treated with palliative intent; as a consequence, stents need to function and last longer in order to avoid repeat procedures. There is also increasing need for meticulous procedure planning, careful selection of the device most appropriate for the individual patient and planned follow-up. Furthermore, as more patients are cured, there will be more issues with resultant long-term side-effects, such as recalcitrant strictures due to radiotherapy or anastomotic scarring, which will have to be addressed. Stent design needs to keep up with the progress of cancer treatment, in order to offer patients the best possible long-term result. This review article attempts to illustrate the changing realities in oesophageal stenting, differences in current stent designs and behaviour, as well as the pressing need to refine and modify devices in order to meet the new challenges.


Subject(s)
Esophageal Diseases/therapy , Stents/trends , Absorbable Implants/trends , Airway Obstruction/etiology , Device Removal/trends , Esophageal Fistula/etiology , Foreign-Body Migration/prevention & control , Humans , Prosthesis Design/trends , Recurrence , Stents/adverse effects
6.
Gut ; 67(6): 1000-1023, 2018 06.
Article in English | MEDLINE | ID: mdl-29478034

ABSTRACT

These are updated guidelines which supersede the original version published in 2004. This work has been endorsed by the Clinical Services and Standards Committee of the British Society of Gastroenterology (BSG) under the auspices of the oesophageal section of the BSG. The original guidelines have undergone extensive revision by the 16 members of the Guideline Development Group with representation from individuals across all relevant disciplines, including the Heartburn Cancer UK charity, a nursing representative and a patient representative. The methodological rigour and transparency of the guideline development processes were appraised using the revised Appraisal of Guidelines for Research and Evaluation (AGREE II) tool.Dilatation of the oesophagus is a relatively high-risk intervention, and is required by an increasing range of disease states. Moreover, there is scarcity of evidence in the literature to guide clinicians on how to safely perform this procedure. These guidelines deal specifically with the dilatation procedure using balloon or bougie devices as a primary treatment strategy for non-malignant narrowing of the oesophagus. The use of stents is outside the remit of this paper; however, for cases of dilatation failure, alternative techniques-including stents-will be listed. The guideline is divided into the following subheadings: (1) patient preparation; (2) the dilatation procedure; (3) aftercare and (4) disease-specific considerations. A systematic literature search was performed. The Grading of Recommendations Assessment, Develop-ment and Evaluation (GRADE) tool was used to evaluate the quality of evidence and decide on the strength of recommendations made.


Subject(s)
Dilatation/methods , Endoscopy/methods , Esophageal Stenosis/surgery , Esophagus/surgery , Dilatation/adverse effects , Esophagus/pathology , Humans , United Kingdom
7.
Gastrointest Endosc ; 75(1): 174-8, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22196815

ABSTRACT

BACKGROUND: When an esophageal stent is placed through the lower esophageal sphincter (LES), gastroesophageal reflux symptoms may persist despite high-dose proton pump inhibitor therapy. A recently developed, short segment, uncovered nitinol stent with a tricuspid-like valve can be placed inside a previously placed esophageal stent. OBJECTIVE: To evaluate the technical feasibility and safety of a reflux control system (RCS) in distally placed esophageal stents. DESIGN: A prospective case series. SETTING: Two tertiary-care referral centers. PATIENTS: This study involved 10 patients who had an "open" stent placed through the LES and 1 patient with severe bile reflux after esophagojejunostomy. INTERVENTION: Placement of an RCS with fluoroscopic and (in selected cases) endoscopic guidance, from April to October 2010. MAIN OUTCOME MEASUREMENTS: Technical success of RCS placement and complications. RESULTS: Placement of an RCS was successful on the first attempt in all patients; complete expansion to the wall of the host stent was confirmed by fluoroscopy in all cases. In 3 patients, the host stent migrated in <1 month with the RCS still inside. In 8 patients, the RCS was in place for a median of 134 days (range 33-225 days). Three patients died because of malignant disease progression. Eight RCSs were removed endoscopically, together with the host stent without complications. RCS migration did not occur. LIMITATIONS: Small number of patients, nonrandomized design, lack of pH measurements. CONCLUSION: Placement of an RCS in a host stent is technically feasible and safe. An RCS can be considered in symptomatic patients with open esophageal stents to prevent gastroesophageal reflux.


Subject(s)
Esophageal Sphincter, Lower , Esophageal Stenosis/therapy , Gastroesophageal Reflux/prevention & control , Stents , Aged , Aged, 80 and over , Feasibility Studies , Female , Gastroesophageal Reflux/drug therapy , Humans , Male , Middle Aged , Prospective Studies , Proton Pump Inhibitors/therapeutic use , Stents/adverse effects , Surveys and Questionnaires , Time Factors , Treatment Outcome
8.
Eur Radiol ; 21(9): 1956-61, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21533633

ABSTRACT

OBJECTIVES: To assess the outcome of self-expandable, biodegradable stent insertion for anastomotic strictures following treatment for rectosigmoid carcinoma. METHODS: Three male patients (median age 66) developed benign strictures after radiotherapy and resection of a recto-sigmoid carcinoma. These were resistant to balloon dilatation and prevented stoma reversal. Biodegradable stent insertion was performed as an experimental treatment on a named-patient basis with approval of the institutional review board. Patients had monthly follow-up with endoscopy and contrast medium enemas to monitor performance and degradation of the stents. RESULTS: All stents were placed successfully without complications after pre-dilatation to 20 mm under fluoroscopic guidance. Stent degradation occurred in all patients 4-5 months following implantation, and long-term anastomotic patency was demonstrated in all. This allowed reversal of the colostomy and physiological defecation in two patients. Reversal was not undertaken in one due to subsequent development of liver metastases. No stent migration or occlusion occurred. CONCLUSIONS: Biodegradable stents can maintain an adequate lumen across anastomotic strictures resistant to balloon dilatation. They seem to allow stricture re-modelling resulting in maintained dilatation after degradation. This potentially allows reversal of a colostomy, which might otherwise be prevented by stricture recurrence.


Subject(s)
Absorbable Implants , Anastomosis, Surgical/adverse effects , Constriction, Pathologic/therapy , Polydioxanone , Rectal Neoplasms/surgery , Stents , Aged , Anastomosis, Surgical/methods , Catheterization/adverse effects , Catheterization/methods , Colectomy/adverse effects , Colectomy/methods , Colostomy/adverse effects , Constriction, Pathologic/etiology , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Staging , Rectal Neoplasms/pathology , Retreatment , Risk Assessment , Sampling Studies , Treatment Outcome
9.
World J Gastrointest Oncol ; 2(4): 197-204, 2010 Apr 15.
Article in English | MEDLINE | ID: mdl-21160598

ABSTRACT

AIM: To assess the relationship between preoperative computed tomography (CT) and postoperative pathological measurements of esophageal tumor length and the prognostic significance of CT tumor length data. METHODS: A retrospective study was carried out in 56 patients who underwent curative esophagogastrectomy. Tumor lengths were measured on the immediate preoperative CT and on the post-operative resection specimens. Inter- and intra-observer variations in CT measurements were assessed. Survival data were collected. RESULTS: There was a weak correlation between CT and pathological tumor length (r = 0.30, P = 0.025). CT lengths were longer than pathological lengths in 68% (38/56) of patients with a mean difference of 1.67 cm (95% CI: 1.18-2.97). The mean difference in measurements by two radiologists was 0.39 cm (95% CI: -0.59-1.44). The mean difference between repeat CT measured tumor length (intra-observer variation) were 0.04 cm (95% CI: -0.59-0.66) and 0.47 cm (95% CI: -0.53-1.47). When stratified, patients not receiving neoadjuvant chemotherapy showed a strong correlation between CT and pathological tumor length (r = 0.69, P = 0.0014, n = 37) than patients that did (r = 0.13, P = 0.43, n = 19). Median survival with CT tumor length > 5.6 cm was poorer than with smaller tumors, but the difference was not statistically significant. CONCLUSION: Esophageal tumor length assessed using CT does not reflect pathological tumor extent and should not be the only modality used for management decisions, particularly for planning radiotherapy.

10.
Gut Liver ; 4 Suppl 1: S89-95, 2010 Sep.
Article in English | MEDLINE | ID: mdl-21103301

ABSTRACT

Recurrent tumour after radical pancreaticoduodenectomy may cause obstruction of the small bowel loop draining the liver. Roux-loop obstruction presents a particular therapeutic challenge, since the postsurgical anatomy usually prevents endoscopic access. Careful multidisciplinary discussion and multimodality preprocedure imaging are essential to accurately demonstrate the cause and anatomical location of the obstruction. Transhepatic or direct percutaneous stent placement should be possible in most cases, thereby avoiding long-term external biliary drainage. Gastropexy T-fasteners will secure the percutaneous access and reduce the risk of bile leakage. The static bile is invariably contaminated by gut bacteria, and systemic sepsis is to be expected. Enteral stents are preferable to biliary stents, and compound covered stents in a sandwich construction are likely to give the best long-term results. Transhepatic and direct percutaneous enteral stent insertion after jejunopexy is illustrated and the literature reviewed.

11.
Eur Radiol ; 20(5): 1069-72, 2010 May.
Article in English | MEDLINE | ID: mdl-19921200

ABSTRACT

BACKGROUND: We present our initial experience with a new biodegradable (BD) esophageal stent in two patients, one for a therapy-resistant benign esophageal stricture, and the other as a temporary measure during curative radiotherapy for oesophageal carcinoma. METHODS: The BD stents need to be loaded into a conventional pull-back delivery system but are then placed in a standard fashion. Pre-dilatation should be avoided to reduce the risk of migration, however if migration occurs the stents can be left to dissolve in the stomach. The stents are radiolucent but easily identified on CT with minimal artefact and thus might even aid with radiotherapy planning. RESULTS: BD stents offer an exciting new strategy for therapy-resistant benign strictures as well as a supportive measure for oesophageal cancer undergoing non-surgical treatment.


Subject(s)
Absorbable Implants , Esophageal Stenosis/therapy , Polydioxanone , Stents , Aged, 80 and over , Conscious Sedation , Esophageal Neoplasms/complications , Esophageal Neoplasms/radiotherapy , Esophageal Stenosis/diagnostic imaging , Esophageal Stenosis/etiology , Humans , Male , Middle Aged , Prosthesis Design , Radiography, Interventional , Registries , Treatment Outcome
12.
Expert Rev Gastroenterol Hepatol ; 2(1): 35-7, 2008 Feb.
Article in English | MEDLINE | ID: mdl-19072368

ABSTRACT

The Society of Gastrointestinal Intervention was founded to provide a multidisciplinary forum for medical staff, scientists and allied health professionals involved in minimally invasive gastrointestinal intervention. Besides providing an international meeting, the society aims to establish a clinical, as well as an academic network among the three main disciplines of gastroenterology, surgery and interventional radiology. A further aim is to promote collaboration between healthcare professionals and industry.


Subject(s)
Gastroenterology , Gastrointestinal Diseases/surgery , Gastrointestinal Diseases/therapy , Humans , Internationality
13.
Cardiovasc Intervent Radiol ; 31(2): 439-43, 2008.
Article in English | MEDLINE | ID: mdl-18066618

ABSTRACT

Percutaneous transhepatic cholangiography (PTC) is a well-established technique for assessing and treating obstructive jaundice. Plastic and self-expanding metal stents can be deployed as an alternative when ERCP is not feasible or hilar strictures require an antegrade approach. Complication rates of percutaneous procedures are low, and are usually related to bile leakage or hemorrhage; pneumoperitoneum following PTC is rare and is usually taken to indicate bowel perforation. We describe two cases of pneumoperitoneum without peritonitis following PTC and stenting, both of which resolved spontaneously with conservative management. The literature is reviewed and possible causes discussed.


Subject(s)
Duodenal Obstruction/therapy , Jaundice, Obstructive/therapy , Pneumoperitoneum/etiology , Stents , Biliary Tract Neoplasms/complications , Cholangiography , Constriction, Pathologic , Contrast Media , Duodenal Obstruction/diagnostic imaging , Duodenal Obstruction/etiology , Humans , Male , Middle Aged , Palliative Care , Pneumoperitoneum/diagnostic imaging , Tomography, X-Ray Computed
16.
Semin Intervent Radiol ; 21(3): 167-79, 2004 Sep.
Article in English | MEDLINE | ID: mdl-21331126

ABSTRACT

Palliative procedures for patients with malignant gastroduodenal obstruction must be readily available, have a rapid onset of action, and be well tolerated by a patient with terminal cancer. Laparoscopic gastroenterostomy and insertion of self-expanding stents are emerging as the current methods of choice.An increasing number of dedicated enteral stents with different properties are now available. These can be placed under fluoroscopic guidance alone or with the help of an endoscope. Endoscopic placement has several advantages but requires good collaboration between the endoscopists and the radiology department. Appropriate imaging and work-up of each case at multidisciplinary meetings is required. Coexisting biliary obstruction may be dealt with endoscopically, but frequently requires percutaneous biliary stent placement prior to duodenal stenting. Reintervention is required in up to 25% of patients, usually due to stent occlusion by further tumor growth. This article suggests strategies for patient assessment, procedure planning, and stent insertion.

17.
Eur J Pain ; 6(6): 467-74, 2002.
Article in English | MEDLINE | ID: mdl-12413435

ABSTRACT

BACKGROUND AND PURPOSE: Shoulder pain is known to retard rehabilitation after stroke. Its causes and prognosis are uncertain. This study describes the incidence of poststroke shoulder pain prospectively, in an unselected stroke population in the first 6 months after stroke and identifies risk factors for developing pain. METHODS: 297 patients with possible stroke were screened and stroke diagnosed in 205 cases. The 152 patients entered the study of which 123 patients were assessed up to 6 months. This cohort, with a mean age of 70.6 years, was examined at 2 weeks, 2, 4, and 6 months. A history of shoulder pain, Barthel score, anxiety and depression score were recorded. Full neurological and rheumatological examination was undertaken, using the contralateral side as a control. Pain outcome and stroke outcome was recorded at subsequent visits. RESULTS: 52 (40%) patients developed shoulder pain on the same side of their stroke. There was a strong association between pain and abnormal shoulder joint examination, ipsilateral sensory abnormalities and arm weakness. Shoulder pain had resolved or improved at 6 months in 41 (80%) of the patients with standard current treatment. CONCLUSIONS: Shoulder pain after stroke occurred in 40% of 123 patients surviving, consenting and not too unwell to participate. This included 52 patients of an original cohort of 205 patients presenting with stroke. Eighty percent of patients made a good recovery with standard treatment Patients with sensory and or motor deficits represent at risk sub-groups.


Subject(s)
Shoulder Pain/etiology , Stroke/complications , Adult , Age Factors , Aged , Aged, 80 and over , Cerebral Infarction/complications , Cerebral Infarction/pathology , Cerebral Infarction/physiopathology , Cohort Studies , Female , Humans , Incidence , Male , Middle Aged , Musculoskeletal Diseases/diagnostic imaging , Musculoskeletal Diseases/pathology , Musculoskeletal Diseases/physiopathology , Prospective Studies , Radiography , Risk Factors , Sex Factors , Shoulder Pain/psychology , Thermosensing/physiology
18.
Radiology ; 225(2): 359-65, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12409567

ABSTRACT

PURPOSE: To compare the effectiveness of an antireflux stent with that of a standard open stent in preventing symptoms of gastroesophageal reflux in patients with inoperable distal esophageal cancer. MATERIALS AND METHODS: Fifty consecutive patients with inoperable distal esophageal tumors underwent placement of either a standard open or an antireflux stent across the cardia. Stents were allocated randomly before assessment of the stricture. All patients were followed up prospectively by the departmental research nurses. Technical and clinical success, reflux symptoms, complications, and reintervention rates were assessed. P values of observed differences were calculated by using the chi(2) and log-rank tests as appropriate. RESULTS: The technical success rate was 100%. Improvement in dysphagia was identical in both groups (three points on a five-point scale). Twenty-four (96%) of 25 patients with standard open stents had symptoms of esophageal reflux; 19 (76%) of 25 required treatment. Three (12%) of 25 patients with antireflux stents reported esophageal reflux; one (4%) of 25 required treatment. This difference was significant (P <.001). There was no significant difference in survival, complications, or reintervention rate. One case of late esophageal perforation occurred in each group. One patient died of aspiration within 24 hours after insertion of a standard open stent; no procedure-related deaths occurred with the antireflux stent. CONCLUSION: This antireflux stent is as safe and effective as the standard open stent in relieving malignant dysphagia and was successful in reducing symptomatic gastroesophageal reflux.


Subject(s)
Adenocarcinoma/therapy , Carcinoma, Squamous Cell/therapy , Cardia , Esophageal Neoplasms/therapy , Gastroesophageal Reflux/prevention & control , Palliative Care , Stents , Stomach Neoplasms/therapy , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/mortality , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/diagnostic imaging , Carcinoma, Squamous Cell/mortality , Esophageal Neoplasms/diagnostic imaging , Esophageal Neoplasms/mortality , Esophageal Stenosis/diagnostic imaging , Esophageal Stenosis/mortality , Esophageal Stenosis/therapy , Female , Gastroesophageal Reflux/diagnostic imaging , Gastroesophageal Reflux/mortality , Humans , Male , Middle Aged , Prosthesis Design , Prosthesis Failure , Radiography , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/mortality , Survival Rate , Treatment Outcome
19.
Cardiovasc Intervent Radiol ; 25(6): 457-66, 2002.
Article in English | MEDLINE | ID: mdl-12391514

ABSTRACT

Benign biliary strictures are most commonly a consequence of injury at laparoscopic cholecystectomy or fibrosis after biliary-enteric anastomosis. These strictures are notoriously difficult to treat and traditionally are managed by resection and fashioning of a choledocho- or hepato-jejunostomy. Promising results are being achieved with newer minimally invasive techniques using endoscopic or percutaneous dilatation and/or stenting and these are likely to play an increasing role in the management. Even low-grade biliary obstruction carries the risks of stone formation, ascending cholangitis and hepatic cirrhosis and it is important to identify and treat this group of patients. There is currently no consensus on which patient should have what type of procedure, and the full range of techniques may not be available in all hospitals. Careful assessment of the risks and likely benefits have to be made on an individual basis. This article reviews the current literature and discusses the options available. The techniques of endoscopic and percutaneous dilatation and stenting are described with evaluation of the likely success and complication rates and compared to the gold standard of biliary-enteric anastomosis.


Subject(s)
Cholestasis, Extrahepatic/therapy , Catheterization , Cholangiography , Cholangiopancreatography, Endoscopic Retrograde , Choledochostomy , Cholestasis, Extrahepatic/diagnosis , Cholestasis, Extrahepatic/etiology , Humans , Stents
20.
Gastrointest Endosc ; 56(2): 317-8; author reply 318-9, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12145623
SELECTION OF CITATIONS
SEARCH DETAIL
...